

POSTER PRESENTATIONS

POSTER SESSION 1: Thursday, November 5th

P1-67 SAFETY AND PHARMACOKINETICS OF ANTI-PROTOFIBRILLAR MAB SAR228810 IN FIRST-IN-MAN STUDY AFTER SINGLE AND MULTIPLE ASCENDING IV AND SC DOSING IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

Bruno Vellas, MD (1), Raphael Dahmen, MD (2), Olivier Nicolas, PhD (3), Valerie Martin, MS (4), Caroline Cohen, PhD (4), Laurent Vermet, MSc (3), Jérôme Barakos, MD (5), Joyce Suhy, PhD (5), Anne Börjesson-Hanson, MD (6), Henrik Östlund, MD (7), Geert Jan Groeneveld, MD (8), Niels Prins, MD (9), Philip Scheltens, MD (9), Kaj Blennow, MD (10), Niels Andreasen, MD (11) (1) *Gérontopôle, CHU Purpan, Toulouse, France*; (2) *Sanofi-Aventis R&D, Frankfurt, Germany*; (3) *Sanofi-Aventis R&D, Montpellier, France*; (4) *Sanofi-Aventis R&D, Chilly-Mazarin, France*; (5) *BioClinica, Medical Imaging, Newark, CA, USA*; (6) *Department of Neuropsychiatry, Sahlgrenska University Hospital, Gothenburg, Sweden*; (7) *Memory Clinic, Skanes University Hospital, Malmö, Sweden*; (8) *Centre for Human Drug Research, Leiden, the Netherlands*; (9) *Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands*; (10) *Clinical Neurochemistry Lab, Dept. of Neuroscience and Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden*; (11) *KI Alzheimer Center, Dept. of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden*

P1-68 SAFETY OF THE 5-HT₆ ANTAGONIST, RVT-101 IN PATIENTS WITH ALZHEIMER'S DISEASE: SUMMARY OF PHASE 2 CLINICAL TRIALS

Ilise Lombardo, MD (1), Geetha Ramaswamy MD (1), Stephen C Piscitelli, PharmD (2), Lawrence T Friedhoff, MD, PhD, FACP (1)

(1) *Axovant Sciences, Inc., New York, NY*; (2) *Roivant Sciences, Inc., New York, NY*

P1-69 STEM CELLS FOR ALZHEIMER'S DISEASE: TRANSITION TO CLINICAL TRIALS

Tristan Bolmont, PhD (1,2), Theo Lasser (1), Alexei Lukashev, PhD (2), Nikolai Tankovich, MD, PhD (3)

(1) *Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland*; (2) *Stemedica International, Epalinges, Switzerland*; (3) *Stemedica Cell Technologies, San Diego, CA, USA*

P1-70 PHARMACOGENETICS SUPPORTED CLINICAL TRIAL TO DELAY ONSET OF MCI DUE TO AD USING PIOGLITAZONE 0.8 MG SR: TOMMORROW STUDY

Kumar Budur, MD, MS (1), Kathleen A. Welsh-Bohmer, PhD (2), Daniel K. Burns, PhD (3), Carl Chiang, PhD (3), Janet O'Neil, MBA (1), Grant Runyan, PhD (1), Meredith Culp, BS (1), Donna G. Crenshaw, PhD (3,4), Michael W. Lutz, PhD (2), Craig A. Metz, PhD (3), Ann M. Saunders, PhD (2), Deborah Yarbrough, MS, MBA (1), Stephen Haneline, MS (3), David Yarnall, MS (3), Eric Lai, PhD (1), Stephen K. Brannan, MD (1), Allen D. Roses, MD (2,3)

(1) *Takeda Development Center Americas, Inc., Deerfield, IL, USA*; (2) *Duke Bryan ADRC, Durham, NC, USA*; (3) *Zinfandel Pharmaceuticals, Inc., Research Triangle Park, NC, USA*; (4) *Department of Medicine, Duke University, Durham, NC, USA*

POSTER SESSION 2: Friday, November 6th

THEME 3: Clinical Trials Imaging

P2-1 CORTICAL THINNING PATTERNS IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE

Eun Ye Lim (1), Jung Hee Cho (1), Yong Soo Shim (1), Yun Jeong Hong (2), Bora Yoon (3), Dong Won Yang (1)

(1) *Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea*, (2) *Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea*, (3) *Konyang University College of Medicine, Daejeon, Korea*

P2-2 GRAY MATTER VOLUMES AND TREATMENT RESPONSE OF PSYCHOTIC SYMPTOMS TO RISPERIDONE IN ANTIPSYCHOTIC-NAÏVE ALZHEIMER'S DISEASE PATIENTS

YoungMin Lee, PhD; Je-Min Park, MD, PhD, Byung-Dae Lee MD, PhD., Eunsoo Moon MD, Hee-Jeong Jeong, MD

Department of Psychiatry, School of Medicine, Pusan National University, Busan, Korea

P2-3 WHITE MATTER MICROSTRUCTURE DISRUPTION IS CORRELATED WITH AMYLOID BURDEN IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. FUNDACIO ACE HEALTHY BRAIN INITIATIVE

O. Rodriguez-Gomez (1) MD, A. Sanabria (1) Msc, A. Pérez-Cordón (1) Msc, D. Sánchez-Ruiz MD (1), S. Ruiz (1), M. Tarragona (1), J. Pavía (2) PhD, F. Campos (2) Msc, A. Vivas (3) MD, M. Gómez (3) MD, M. Tejero (3) RT, M. Alegret (1) PhD, A. Espinosa (1) Msc, G. Ortega (1) PhD, C. Abdelnour (1) MD, I. Hernández (1) MD PhD, A. Ruiz (1) MD PhD J. Giménez (3) MD, F. Lomeña (2) MD, L. Tárraga (1) Msc, O. Sotolongo-Grau (1) PhD, M. Boada (1) MD PhD

(1) *Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain*; (2) *Servei de Medicina Nuclear, Hospital Clínic i Provincial. Barcelona, Spain*; (3) *Departament de Diagnòstic per la Imatge. Clínica Corachan, Barcelona, Spain*

P2-4 PET STUDIES WITH RVT-101 IN HEALTHY VOLUNTEERS DEMONSTRATE HIGH OCCUPANCY OF THE 5HT₆ RECEPTOR

Ilise Lombardo, MD (1), Geetha Ramaswamy, MD (1), Stephen C. Piscitelli, PharmD (2), Lawrence Friedhoff, MD, PhD, FACP (1)

(1) *Axovant Sciences, Inc.*; (2) *Roivant Sciences, Inc.*

POSTER PRESENTATIONS

POSTER SESSION 2: Friday, November 6th

- P2-5** **FIRST CLINICAL APPLICATION OF THE AUTOMATIC SEGMENTATION METHOD OF HIPPOCAMPAL SUBFIELDS (ASHS) IN (PRODRIMAL) ALZHEIMER'S DISEASE: A POTENTIAL BIOMARKER**
Eske Christiane Gertje, MD (1), John Pluta (2), Sandhitsu Das, PhD (2), Andreas Engelhardt, MD (1), Lauren Mancuso (3), Dasha Kliot (3), Paul Yushkevich, PhD (2), David Wolk, MD (3)
(1) Department of Neurology, University of Oldenburg, Oldenburg, Germany; (2) Penn Image Computing and Science Laboratory, Department of Radiology, University of Pennsylvania, Philadelphia, USA; (3) Penn Memory Center, Department of Neurology, University of Pennsylvania, Philadelphia, USA
- P2-6** **INTEGRATION OF FLORBETAPIR PET AND CEREBROSPINAL FLUID A β 42 TO DEFINE AMYLOID BURDEN IN ALZHEIMER'S DISEASE**
Gerald Novak, MD (1), Lisa Ford, MD (1), Mahesh Samtani PhD (1), Mark Forrest Gordon, MD (2), for the Alzheimer's Neuroimaging Initiative and the European Medical Information Framework Alzheimer's Disease
(1) Janssen Pharmaceuticals, LLC, Titusville, NJ, USA ; (2) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
- P2-7** **DIFFERENTIATING THE EFFECTS OF DOWN SYNDROME AND ALZHEIMER'S DISEASE UPON NEURONAL FUNCTION AND BRAIN VOLUME**
Dawn Matthews, MS MBA (1), Ana Lukic, PhD (1), Randolph Andrews, MS (1), Boris Marendic, PhD (1), James Brewer, PhD (2), Lisa Mosconi, PhD (3), Stephen Strother, PhD (1,4), Miles Wernick, PhD (1,5), Mark Schmidt, MD (6), Michael Rafii, MD PhD (2), for the Alzheimer's Disease Neuroimaging Initiative
(1) ADM Diagnostics, Chicago, Illinois, USA; (2) University of California San Diego School of Medicine, San Diego, California, USA; (3) New York University, New York, USA; (4) Baycrest Hospital, Toronto, ON, Canada; (5) Illinois Institute of Technology, Chicago, Illinois, USA; (6) Janssen Research and Development, Beerse, Belgium
- P2-8** **INCREASED UTILIZATION OF IMAGING IN ALZHEIMER DISEASE (AD) TRIALS: IMPACT ON PATIENT RECRUITMENT, RETENTION AND LOGISTICS**
Kohkan Shamsi MD, PhD
Principal at RadMD LLC, Pipersville, PA - USA
- P2-9** **HIPPOCAMPUS VOLUME LOSS IN ALZHEIMER'S DISEASE PATIENTS: EFFECT OF TREATMENT WITH CHOLINE ALPHOSCERATE IN ADDITION TO CHOLINESTERASE INHIBITOR**
Enea Traini, PhD (1), Anna Carotenuto, PhD (1,2), Angiola Maria Fasanaro, MD (1,2), Raffaele Rea, PhD (1,2), Francesco Amenta, MD (1)
(1) Centre for Clinical Research, Telemedicine and Telepharmacy, University of Camerino, Camerino, (2) Alzheimer Evaluation Unit, National Hospital, "A. Cardarelli", Naples, Italy
- P2-10** **PRESUBICULUM VOLUME CHANGES IN MILD COGNITIVE IMPAIRMENT PATIENTS WITH AD PATHOLOGY**
Moira Marziconi, PhD (1), Jorge Jovicich, PhD (2), Elena Rolandi, MSc (1), Samantha Galluzzi, MD (1), Flavio Nobili, MD (3), Mira Didic, MD (4,5), David Bartrés-Faz, MD (6), Ute Fiedler, (7), Peter Schonknecht, MD (8), Pierre Payoux, MD (9,10), Alberto Beltramello, MD (11), Andrea Soricelli, MD (12,13), Lucilla Parnetti, MD (14), Magda Tsolaki, MD (15), Paolo Maria Rossini, MD (16,17), Philip Scheltens, MD (18), Gianluigi Forloni, PhD (19), Regis Bordet, MD (20), Olivier Blin, MD (21), Giovanni Battista Frisoni, MD (1,22); on behalf of the PharmaCog Consortium
(1) Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; (2) Center for Mind/Brain Sciences, University of Trento, Trento, Italy; (3) Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINO GMI), University of Genoa, Genoa, Italy; (4) APHM, CHU Timone, Service de Neurologie et Neuropsychologie, Marseille, France; (5) Aix-Marseille Université, INSERM U 1106, Marseille, France; (6) Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona and IDIBAPS, Barcelona, Spain; (7) LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany; (8) Department of Neuroradiology, University Hospital Leipzig, Leipzig, Germany; (9) INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse, France; (10) Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU Purpan, Toulouse, France; (11) Department of Neuroradiology, General Hospital, Verona, Italy; (12) IRCCS SDN, Naples, Italy; (13) University of Naples Parthenope, Naples, Italy; (14) Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy; (15) 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece; (16) Dept. Geriatrics, Neuroscience & Orthopaedics, Catholic University, Policlinic Gemelli, Rome, Italy; (17) IRCCS S.Raffaele Pisana, Rome, Italy; (18) Alzheimer Centre and Department of Neurology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands; (19) Neuroscience Department, IRCCS Istituto di Ricerche Farmacologiche «Mario Negri», Milano, Italy; (20) Department of Pharmacology, EA1046, University of Lille Nord de France, Lille Cedex, France; (21) Pharmacology, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University-CNRS UMR 7289, Marseille, France; (22) Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
- P2-11** **ROBUSTNESS OF 18F-FLORBETABEN SUVR CUTOFF QUANTIFICATION ACROSS REFERENCE REGIONS AND STANDARDS OF TRUTH**
Santiago Bullich, PhD (1), Susan De Santi, PhD (2), John Seibyl, MD (3), Ana M. Catafau, MD, PhD (1)
(1) Piramal Imaging GmbH, Berlin, Germany; (2) Piramal Pharma Inc, Boston, MA, USA; (3) Molecular Neuroimaging, New Haven, CT, USA

POSTER PRESENTATIONS

POSTER SESSION 2: Friday, November 6th

P2-12 CLASSIFICATION OF POSITIVE AND NEGATIVE 18F-FLORBETABEN SCANS: COMPARISON OF SUVR CUTOFF QUANTIFICATION AND VISUAL ASSESSMENT PERFORMANCE

Santiago Bullich, PhD (1), Susan De Santi, PhD (2), John Seibyl, MD (3), [Ana M. Catafau](#), MD, PhD (1)
(1) Piramal Imaging GmbH, Berlin, Germany; (2) Piramal Pharma Inc, Boston, MA, USA; (3) Molecular Neuroimaging, New Haven, CT, USA

P2-13 SINGLE-CASE VOXEL-BASED ANALYSIS OF FLORBETAPIR-PET

[Altomare Daniele](#), MS (1), Bosco Paolo, PhD (1), Guerra Ugo Paolo, MD (2), Paghera Barbara, MD (3), Festari Cristina, MS (1), Pasqualetti Patrizio, MS (4), Muscio Cristina, MS (1,5), Pievani Michela, PhD (1), Padovani Alessandro, MD (6), Frisoni Giovanni Battista, MD (1,7), Boccardi Marina, PhD (1)
(1) Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy; (2) Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy; (3) Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, Brescia, Italy; (4) Fatebenefratelli Hospital of Isola Tiberina, Roma, Italy; (5) European Foundation Biomedical Research (FERB), Center of Excellence Alzheimer, Ospedale Briolini of Gazzaniga, Bergamo, Italy; (6) Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy; (7) Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland

P2-14 RELATIONSHIPS BETWEEN COGNITIVE ASSESSMENTS AND SPATIAL DISTRIBUTION OF NEUROPATHOLOGICAL TAU AS ASSESSED BY 18F AV-1451 PET SCANNING

[Michael D. Devous, Sr.](#), Michael Navitsky, Ian Kennedy, Abhinay D. Joshi, Ming Lu, Michael J. Pontecorvo, Mark A. Mintun
Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

P2-15 LOW DOSE WHOLE BRAIN IRRADIATION AS A POTENTIAL TREATMENT OF ALZHEIMER'S DISEASE

[James Fontanesi](#) MD (1), Daniel B. Michael MD, PhD (1), Brian Marples PhD (2), George D. Wilson PhD (2), Alvaro A. Martinez MD (3), Scott E. Bowen PhD (4)
(1) Department of Neurosurgery, William Beaumont Hospital/Oakland University School of Medicine, Royal Oak, Michigan USA; (2) Department of Radiation Oncology, William Beaumont Hospital/Oakland University School of Medicine, Royal Oak, Michigan USA; (3) Department of Radiation Oncology, 21 Century Oncology, Farmington Hills, Michigan USA; (4) Department of Psychology, Wayne State University, Detroit, Michigan USA

P2-16 SNP PROFILING AS AN APPROACH TO RISK STRATIFICATION FOR FUTURE COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT (MCI)

[Valentina Escott-Price](#), PhD (1), Richard Pither, BSc, PhD (2), Harald Hampel, MD, PhD (3), Julie Davis, BSc, MSc (2), John Hardy, PhD, DSc (4)
(1) Cardiff University, Cardiff, United Kingdom, (2) Cytox Ltd, UK, Oxford, United Kingdom, (3) Université Pierre et Marie Curie, Paris, France, (4) UCL Institute of Neurology, London, United Kingdom

P2-17 IDENTIFICATION OF POTENTIAL TARGETS FOR BRAIN STIMULATION IN AD AND BVFTD: A META-ANALYSIS OF FMRI STUDIES

[Michela Pievani](#), PhD (1), Lorenzo Pini, MS (1), Clarissa Ferrari, PhD (2), Maria Cotelli, PhD (3), Rosa Manenti, PhD (3), Giovanni B. Frisoni, MD (1,4)
(1) Lab Alzheimer's Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy; (2) IRCCS Fatebenefratelli, Brescia, Italy; (3) Neuropsychology Unit, IRCCS Fatebenefratelli, Brescia, Italy; (4) University Hospitals and University of Geneva, Geneva, Switzerland

P2-18 DOES HIPPOCAMPAL VOLUMETRY IMPACT ON DIAGNOSTIC CONFIDENCE IN ALZHEIMER'S DISEASE? AN EADC STUDY

[Paolo Bosco](#), PhD (1), Alberto Redolfi, MSc (1), Martina Bocchetta, MSc (1,2), Clarissa Ferrari, PhD (3), Samantha Galluzzi, MD (1), Mark Austin, PhD (4), Louis Collins, PhD (5), Andrea Chincarini, PhD (6), Alexis Roche, PhD (7), Francesco Sensi, MSc (6), Robin Wolz, PhD (4), Montserrat Alegret, PhD (8), Mircea Balasa, MD (9), Christine Bastin, PhD (10), Anastasia Bougea, PhD (11), Derya Durusu Emek-Sava, PhD (12,13), Sebastiaan Engelborghs, MD, PhD (14,15), Timo Grimm, MD, PhD (16), Ntovas Konstantinos (17), Milica G. Kramberger, MD, PhD (18), Brian Lawlor, MD (19), Gorana Mandic Stojmenovic, MD (20), Patrizia Mecocci, MD (21), Jose Luis Molinuevo, MD (9), Ricardo Morais, MD (22), Ellis Niemantsverdriet, MSc (14), Flavio Nobili, MD (23), Sarah O'Dwyer, MSc (11), George P. Paraskevas, MD (11), Luca Pelini, MD (20), Agnese Picco, MD (23), Eric Salmon, MD (10), Isabel Santana, MD, PhD (24), Oscar Sotolongo-Grau, PhD (8), Elka Stefanova, MD, PhD (20,25), Katarina Surlan Popovic, MD, PhD (26), Magda Tsolaki, MD (17), Görsev G. Yener, MD, PhD (12,13,27), Giovanni B. Frisoni, MD (1,28)
(1) IRCCS Fatebenefratelli, Brescia, Italy; (2) University of Brescia, Brescia, Italy; (3) IRCCS Fatebenefratelli, Brescia, Italy; (4) IXICO Plc, London, UK; (5) McGill University, Montreal, Quebec, Canada; (6) INFN, Genova, Italy; (7) Siemens, Lausanne, Switzerland (8) Fundació ACE, Barcelona, Spain; (9) Hospital Clinic, Barcelona, Spain; (10) University of Liège, Belgium; (11) Medical school of Athens, Greece; (12) Dokuz Eylül University, Izmir, Turkey; (13) Department of Dokuz Eylül University, Izmir, Turkey; (14) University of Antwerp, Antwerp, Belgium; (15) Hospital Network Antwerp (ZNA) Hoge Beuken and Middelheim, Antwerp, Belgium; (16) Technische Universität München, Munich, Germany (17) Aristotle University of Thessaloniki, Greece (18) University Medical Center Ljubljana; (19) St. James's Hospital, Dublin, Ireland; (20) Institute of Neurology, CCS, Belgrade Serbia; (21) Università degli Studi di Perugia, Perugia, Italy; (22) Hospital Universitário de Coimbra, Coimbra, Portugal; (23) University of Genoa, Italy; (24) Hospital Universitário de Coimbra, Coimbra, Portugal; (25) Faculty of Medicine, University of Belgrade, Belgrade, Serbia; (26) University Medical Center Ljubljana; (27) Dokuz Eylül University, Izmir, Turkey; (28) University Hospitals and University of Geneva, Geneva, Switzerland

POSTER PRESENTATIONS

POSTER SESSION 2: Friday, November 6th

P2-19 INABILITY OF THREE FUNCTIONAL MRI CONNECTIVITY ENDPOINTS TO DETECT PROGRESSION IN CLINICAL TRIAL PATIENTS WITH ALZHEIMER'S DISEASE

Alexandre Coimbra, PhD (1), David Clayton, PhD (1), Faraji Farshid, PhD (1), Lee Honinberg, PhD (2), Robert Paul, MD, PhD (2), Alex deCrespigny PhD (1)

(1) Genentech, gRed Clinical Imaging Group, South San Francisco, California, USA; (2) Genentech, gRed ITGR, South San Francisco, California, USA

P2-20 CORTICAL THICKENING AND DIFFUSIVITY CHANGES IN PRECLINICAL ALZHEIMER'S DISEASE

Juan Fortea, MD, PhD (1)*, Victor Montal, MSc (1)*, Eduard Vilaplana, MSc (1), Daniel Alcolea, MD (1), Jordi Pegueroles, MSc (1), Frederic Sampedro, MSc (1,2), María Carmona-Iragui, MD (1), Jordi Clarimón, PhD (1), Sofía González, MD (3), Pablo Martínez-Lage, MD, PhD (4), Pascual Sánchez-Juan, MD, PhD (5), Rafael Blesa, MD, PhD (1), Alberto Lleó, MD, PhD (1)

(1) Department of Neurology, IIB Sant Pau - Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; (2) Department of Nuclear Medicine, IIB Sant Pau - Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; (3) Department of Radiology, Hospital del Mar, Barcelona, Spain; (4) Fundació CITA-alzhéimer Fundazioa, San Sebastián, Spain; (5) Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Santander, Spain- Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain. The SIGNAL study

P2-21 IDENTIFICATION AND FIRST-IN-HUMAN EVALUATION OF GENENTECH TAU PROBE 1 ([18F]JGTP1)

Sandra Sanabria Bohorquez, PhD (1), Olivier Barret, PhD (2), Gilles Tamagnan, PhD (2), Jeff Tinianow, MS (3), Annie Ogasawara, BS (3), Simon Williams, PhD (3), Alex de Crespigny, PhD (1), Gai Ayalon, PhD (4), Geoffrey Kerchner, MD PhD (5), William Cho, MD PhD (5), Danna Jennings, MD (2), John P. Seibyl, MD (2), Ken Marek, MD (2), Robby Weimer, PhD (3), Jan Marik, PhD (3)

(1) Clinical Imaging Group, (3) Department of Biomedical Imaging, (4) Department of Neuroscience and (5) Early Clinical Development, Genentech, Inc., South San Francisco, USA (2) Molecular NeuroImaging LLC, New Haven, CT, USA

P2-22 INTEGRATION OF EADC-ADNI HARMONISED HIPPOCAMPUS LABELS INTO THE LEAP AUTOMATED SEGMENTATION TECHNIQUE

Katherine R. Gray, PhD (1,2), Hoi Kin Kwan, MSc (1), Robin Wolz, PhD (1,2), Derek L.G. Hill, PhD (1)

(1) IXICO plc., London, United Kingdom; (2) Biomedical Image Analysis Group, Imperial College London, United Kingdom

P2-23 LONGITUDINAL FDG-PET CHANGES IN COGNITIVELY NORMAL ADNI SUBJECTS USING TEMPORAL CORRELATION ANALYSIS

Sepideh Shokouhi

Vanderbilt University Institute of Imaging Science, Nashville, TN, USA

THEME 4: Clinical Trials Biomarkers

P2-24 TEST-RETEST REPRODUCIBILITY OF CSF BIOMARKER MEASUREMENTS IN ADNI

Weining Robieson, PhD (1), Deli Wang, MD, PhD (1), Yunzhi Lin, PhD (1), Davis Ryman, MD, PhD (1), Nuno Mendonca, MD (2), Laura Gault, MD, PhD (1)

(1) AbbVie Inc., North Chicago, Illinois, USA; (2) AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

P2-25 CLINICAL DIAGNOSIS AND THE CONGRUENCE OF BIOMARKER CONSTELLATION IN AD

Hermann-Josef Gertz MD (1), David Weise, MD (1,2), Carolin Awissus (1), Solveig Tiepolt MD (3), Henryk Barthel MD (3), Osama Sabir, MD (3), Karl-Titus Hoffmann MD (4), Donald Lobsien MD (4), Thorsten Kaiser MD (5)

(1) Department of Psychiatry, University of Leipzig, Leipzig, Germany; (2) Department of Neurology, University of Leipzig, Leipzig, Germany; (3) Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; (4) Department of Neuroradiology, University of Leipzig, Leipzig, Germany; (5) Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany

P2-26 A FRAGMENT OF BREVICAN AS A NOVEL BLOOD BIOMARKER OF ALZHEIMER'S DISEASE

Dilek Inekci (1), Ditte Jonesco (1), Ole J. Vilholm (2), Morten Karsdal (1), Kim Henriksen (1)

(1) Biomarkers and Research, Nordic Bioscience, Herlev, Denmark; (2) Department of Neurology, Lillebaelt Hospital, Vejle, Denmark

P2-27 ABETA LEVELS IN THE JAGULAR VEIN AND ABETA OLIGOMER LEVELS IN CSF CAN BE CHANGED AFTER THE TREATMENT OF IVIG FOR AD

Takashi Kasai, MD, PhD, (1), Masaki Kondo, MD, PhD, (1), Ryotarou Ishii, MD, PhD, (1), Toshiki Mizuno, MD, PhD, (1), Takahiko Tokuda, MD, PhD, (2)

(1) Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan; (2) Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, Kyoto, Japan

P2-28 APOLIPOPROTEIN E GENOTYPE IN SUBJECTS WITH SUBJECTIVE MEMORY IMPAIRMENT ASSESSED FOR OBJECTIVE COGNITIVE IMPAIRMENT

Georg Adler, MD, Binder J, Yvonne Lembach, PhD

Institut fuer Studien zur Psychischen Gesundheit (ISPG), Mannheim, Germany

POSTER PRESENTATIONS

POSTER SESSION 2: Friday, November 6th

- P2-29** **A FAST AND COST-EFFECTIVE METHOD FOR APOLIPOPROTEIN E ISOTYPING AS AN ALTERNATIVE TO APOE GENOTYPING FOR PATIENT STRATIFICATION IN CLINICAL TRIALS**
Miguel Calero, PhD (1); Olga Calero, PhD (3); Andrés Rodríguez-Martín (2); Luis Gil-de-Gómez, PhD (2); Sergi Gassó, PhD (4); Luis García-Albert, PhD (5)
(1) Chronic Disease Programme, CIBERNED, and CIEN Foundation-Queen Sofia Foundation, Instituto de Salud Carlos III. Madrid, Spain; (2) Biocross, S.L., Valladolid, Spain; (3) CIBERNED and Chronic Disease Programme, Instituto de Salud Carlos III. Madrid, Spain; (4) Pragmatic Diagnostics S.L., Bellaterra (Cerdanyola del Vallès), Barcelona, Spain; (5) Chronic Disease Programme, Instituto de Salud Carlos III. Madrid, Spain
- P2-30** **TECHNICAL PERFORMANCE OF A NOVEL FULLY AUTOMATED ELECTROCHEMILUMINESCENCE IMMUNOASSAY FOR THE QUANTITATION OF A β 1-42 IN HUMAN CEREBROSPINAL FLUID (CSF)**
Tobias Bittner, PhD, Christina Rabe, PhD, Ekaterina Manuilova, MSc, and Peter Heiss, PhD
Roche Diagnostics GmbH, Penzberg, Germany
- P2-31** **RETINAL ASSESSMENT WITH OPTICAL COHERENCE TOMOGRAPHY IN ALZHEIMER DISEASE AND MILD COGNITIVE IMPAIRMENT**
D. Sánchez-Ruiz (1) MD, M. Castilla (1) MD, O. Rodriguez-Gomez (1) MD, J. Serra (1), A. Ciudin (2) MD, O. Simó-Servat (2) MD, C. Hernández (2) MD PhD, A. Mauleón (1) MD, M. Rosende-Roca (1) MD, L. Vargas (1) MD, C. Abdelnour (1) MD, G. Ortega (1) MS PhD, A. Espinosa (1) MS, I. Hernández (1) MD PhD, M. Alegret (1) MS PhD, R. Simó (2) MD PhD, A. Ruiz (1) MD PhD, L. Tárraga (1) MS, M. Boada (1) MD PhD
(1) Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; (2) Diabetes and Metabolism Department. Vall d'Hebron Research Institute, VHIR, Barcelona, Spain
- P2-32** **ACCURATE MEASUREMENT OF TAU IN SERUM AND PLASMA USING A NOVEL TECHNOLOGY WITH FG/ML SENSITIVITY**
Galina N. Nikolenko, PhD, Robert Umek, PhD, Laukik Sardesai, MS, Anu Mathew, PhD, John H. Kenten, PhD, Eli N. Glezer, PhD, and Jacob N. Wohlstadter
Meso Scale Discovery (MSD), Rockville, MD, USA
- P2-33** **PREDICTORS OF AMYLOID POSITIVITY IN A STUDY SAMPLE WITH AMNESTIC MILD COGNITIVE IMPAIRMENT**
Yuki Mukai, MD (1), Yi Mo, PhD (1), Cyrille Sur, PhD (1), Tiffini Voss, MD (1), Ying Zhang, PhD (1), James Kost, PhD (1), Gregory Klein, PhD (2), Mehul Sampat, PhD (2), Davis Staewon, BSc (2), Derk Purcell, MD (2,3,4), Jerome Barakos, MD (2,3), Joyce Suh, PhD (2), David Michelson, MD (1), Michael Egan, MD (1)
(1) Merck & Co., Inc., Kenilworth, NJ, USA; (2) BioClinica, Newark, CA, USA; (3) California Pacific Medical Center, San Francisco, CA, USA; (4) University of California San Francisco, San Francisco, CA, USA
- P2-34** **USE OF STABLE ISOTOPE LABELING AMINO ACID IN-VIVO (SILAV) TO MONITOR CSF PROTEIN METABOLISM IN ALZHEIMER'S DISEASE PATIENTS**
S. Lehmann (1), G. Gras Combe (2), J. Vialaret (1), L. Bauchet (2), ML. Tall (3), O. Hanon (4), A. Gabelle (1,5), C. Hirtz (1)
(1) CHRU de Montpellier and Université de Montpellier, IRMB, Laboratoire de Biochimie Protéomique Clinique, Montpellier, France; (2) Service de Neurochirurgie, CHRU de Montpellier, hôpital Gui de Chauliac, Montpellier, and Université de Montpellier; Montpellier, France; (3) Pharmacie, Groupement Hospitalier Edouard Herriot, Lyon, France. (4) AP-HP, Hôpital Broca, Service de Gériatrie, Paris, France. Université Paris Descartes, Sorbonne Paris Cité, Paris, France; (5) Centre Mémoire Ressources Recherche Languedoc-Roussillon, CHRU de Montpellier, hôpital Gui de Chauliac, Montpellier, and Université de Montpellier; Montpellier, France
- P2-35** **HEADING FOR SUPERIOR ANALYTICAL PERFORMANCE: FROM INNOTEST TO THE FULLY AUTOMATED CHEMILUMINESCENT β -AMYLOID (1-42) AND TOTAL TAU ASSAYS ON THE LUMIPULSE® G INSTRUMENT SERIES**
Annelies Vandersteen, Sandra Pereson, Filip Dekeyser, Tinne Dumont, Katrien De Vuyst, Wim Vandezande, Kathleen Gorteman, Paul Vandepoosele, Pieter Van Hecke, Martine Dauwe, Geert Jannes
Fujirebio Europe N.V., Gent, Belgium
- P2-36** **METABOLIC BIOMARKERS OF COGNITIVE DECLINE IN HEALTHY POSTMENOPAUSAL WOMEN**
Roberta Diaz Brinton, PhD; Jamaica R. Rettberg, PhD, Howard N. Hodis, MD, Victor W. Henderson, MD; Wendy J. Mack PhD.
(1) Pharmacology & Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA; (2) 23andMe, Mountain View, CA, USA; (3) Department of Medicine, University of Southern California, Los Angeles, CA, USA; (4) Department of Neurology, Stanford University, Palo Alto, CA, USA; (5) Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA
- P2-37** **CHARACTERIZATION OF ALBUMIN OXIDATION STATUS IN ALZHEIMER'S DISEASE PATIENTS**
Montserrat Costa (1), Raquel Horrillo (1), Ana Maria Ortiz (1), Alba Pérez (1), Pol Herrero (2,3), Núria Canela (2,3), Mercè Boada (4), Agustín Ruiz (4), Isabel Hernández (4), Natalia Afonso (1), Mireia Torres (1), Salvador Grancha (1), Juan Ignacio Jorquera (1)
(1) R&D and Clinical Operations, Bioscience Industrial Group, Grifols S.A., Barcelona, Spain; (2) Centre for Omic Sciences (COS), Universitat Rovira I Virgili (URV) Reus, Spain; (3) Centre Tecnològic en Nutrició I Salut (CTNS), Reus, Spain; (4) Fundació ACE (Barcelona Alzheimer Treatment & Research Center), Barcelona, Spain

POSTER PRESENTATIONS

POSTER SESSION 2: Friday, November 6th

- P2-38 ALZHEIMER'S DISEASE CSF BIOMARKERS PREDICT COGNITIVE DECLINE IN DLB**
Carla Abdelnour (1), Elisabet Londos (2), Milica Kramberger (3), Inger van Steenoven (4), Evelien Lemstra (4), Mercè Boada (1), Dag Aarsland (5,6) on behalf of the JPND DLB study group
(1) *Fundació ACE Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain*; (2) *Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden*; (3) *Department of Neurology, University Medical Centre, Ljubljana, Slovenia*; (4) *Alzheimer Centre, Department of Neurology, VU Medical Centre, Amsterdam, The Netherlands*; (5) *Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institute, Stockholm, Sweden*; (6) *Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway*
-
- P2-39 ANALYSIS OF REST PROTEIN EXPRESSION IN ALZHEIMER'S DISEASE UTILIZING MONOCLONAL ANTIBODIES TO THIS BIOMARKER**
Richard J. Kascsak (1), Ph.D., Regina B. Kascsak (1), B.S., Thomas Wisniewski (2), M.D.
(1) *New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY*; (2) *New York University School of Medicine, New York, NY*
-
- P2-40 MULTIPLEX CSF PHOSPHO-TAU SITE-SPECIFIC QUANTIFICATION BY MASS SPECTROMETRY TO ENABLE EARLIER DIAGNOSIS AND PHARMACODYNAMICS BIOMARKERS**
Ian Pike PhD (1), Claire Russell PhD (1), Vikram Mitra (1), Henrik Zetterberg PhD (2,3), Mikko Hiltunen PhD (4), Malcolm Ward PhD (1)
(1) *Proteome Sciences plc, Cobham, UK*; (2) *University of Gothenburg, Gothenburg, Sweden*; (3) *UCL, Queen Square, London, UK*; (4) *University of Eastern Finland, Kuopio, Finland*
-
- P2-41 INFLAMMATORY MARKERS IN ALZHEIMER'S DISEASE WITH VARIOUS DEGREES OF DEMENTIA SEVERITY**
Tatyana Klyushnik, Lyubov Androsova, Natalia Mikhaylova, Svetlana Zozulya, Alexander Dupin, Svetlana Gavrilova
FSGI "The Mental Health Research Centre", Moscow, Russia
-
- P2-42 THE ALZHEIMER'S METABOLOME: IDENTIFICATION OF NOVEL MARKERS AND TREATMENT TARGETS**
Jon B. Toledo, MD (1), J Will. Thompson, PhD (2), Lisa St. John-Williams (2), PhD, Guido Dallmann (4), Xianlin Han, PhD (3), Jessica D. Tenenbaum (2), PhD, Therese Koal (4), Siamak Mahmoudiandehkordi (2), Alison Motsinger, PhD (2), PhD, Sungeun Kim, PhD (5), Vijitha Senanayake, PhD (6), Andrew J. Saykin, PsyD (5), Rebecca Baillie, PhD (3), Leslie M. Shaw, PhD (1), John Q. Trojanowski, MD, PhD (1), Dayan B. Goodenowe, PhD (6); Mitchel A. Kling, MD (1), Arthur Moseley (2), Rima Kaddurah-Daouk, PhD (2) For the Alzheimer Disease Neuroimaging Initiative and the Alzheimer's Disease Metabolomics Consortium
(1) *Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA*; (2) *Duke University Medical Center, Durham, NC, USA*; (3) *Sanford-Burnham Medical Research Institute, Orlando, FL, USA*; (4) *BIOCRATES Life Sciences AG, Innsbruck, Austria*; (5) *Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA*; (6) *Phenomenome Discoveries Inc., Saskatoon, SK, Canada*
-
- P2-43 CORRELATION OF LOAD-RELATED APOE4 AND WTGSTO1 VARIANTS WITH MILD COGNITIVE IMPAIRMENT DEPENDS ON THE CLASSIFYING NEUROPSYCHOLOGICAL TEST**
Ellen Umlauf (1), Eduard Rappold (1), Bettina Schiller (1), Petra Fuchs (2), Michael Rainer (3), Brigitte Wolf (4), Maria Zellner (1)
(1) *Medical University of Vienna, Institute of Physiology, Vienna, Austria*; (2) *SMZ Otto Wagner Spital, 3rd Department of Psychiatry, Vienna, Austria*; (3) *SMZ Ost, Karl Landsteiner Institut für Gedächtnis- und Alzheimerforschung, Vienna, Austria*; (4) *Medical University of Vienna, Department of Surgery and Surgical Research, Vienna, Austria*
-
- P2-44 PLASMA TAU IN ALZHEIMER'S DISEASE**
Niklas Mattsson, MD, PhD (1), Henrik Zetterberg, MD, PhD (2), Shorena Janelidze, PhD (1), Ulf Andreasson, PhD (2), Erik Stomrud, MD, PhD (3), Sebastian Palmqvist, MD, PhD (3), David Baker, PhD (3), Cristina A. Tan Hehir, PhD (4), Andreas Jeromin, PhD (5), David Hanlon, PhD (5), Leslie M. Shaw, PhD (6), John Q. Trojanowski, MD, PhD (6), Michael W. Weiner, MD (7), Oskar Hansson, MD, PhD (1), Kaj Blennow, MD, PhD (2)
(1) *Lund University, Sweden*; (2) *University of Gothenburg, Sweden*; (3) *Janssen R&D (J&J)*; (4) *GE Global Research*; (5) *Quanterix*; (6) *University of Pennsylvania, USA*; (7) *University of California San Francisco, USA*
-
- P2-45 ULTRA-SENSITIVE SINGLE MOLECULAR ARRAY (SIMOA) TECHNOLOGY FOR THE DETECTION OF TAU IN BLOOD: CNS APPLICATIONS**
Amelie Castro, Lei Chang, PhD, David Hanlon, PhD, David Wilson, PhD, Andreas Jeromin, PhD
Quanterix Corporation Lexington, MA, USA
-
- P2-46 OLFACTORY DEFICITS PREDICT RESPONSE TO CHOLINESTERASE INHIBITORS IN MCI DUE TO ALZHEIMER DISEASE**
Davangere P. Devanand, MD (1); Seonjoo Lee, Ph.D (2), Yaakov Stern, Ph.D (3); Gregory H. Pelton, M.D. (1)
(1) *Division of Geriatric Psychiatry, Columbia University Medical Center*; (2) *Biostatistics, Mailman School of Public Health, Columbia University*; (3) *Department of Neurology, Taub Institute, Columbia University Medical Center, New York City, NY, USA*

POSTER PRESENTATIONS

POSTER SESSION 2: Friday, November 6th

P2-47 HEALTH PLAN FOR ADULT SUBJECTS WITH DOWN SYNDROME AND DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI) PROJECT

Sebastian Videla MD PhD (1); María Carmona-Iragui MD PhD (1,2); Laura Videla BSc (1); Susana Fernández MD (1); Bessy Benejam BSc (1); Daniel Alcolea MD (2); Valle Camacho MD (3); Sandra Giménez MD (4); Sofía González-Ortiz MD (5); Eduard Vilaplana BSc (1); Jordi Clarimon BSc (2); Rafael Blesa MD PhD (2); Alberto Lleó MD PhD (2); Juan Fortea MD PhD (1,2)
(1) *Fundació Catalana Síndrome de Down. Barcelona, Spain;* (2) *Memory Unit, Department of Neurology. Hospital de la Santa Creu i Sant Pau. Biomedical Research Institute Sant Pau. Barcelona, Spain;* (3) *Department of Nuclear Medicine. Hospital de la Santa Creu i Sant Pau. Biomedical Research Institute Sant Pau. Barcelona, Spain;* (4) *CIM Sant Pau. Biomedical Research Institute Sant Pau. Barcelona, Spain;* (5) *Radiology Department. Hospital del Mar. Barcelona, Spain*

P2-48 SERUM PLASMA LOGS, COGNITION, AND COGNITIVE DECLINE IN ALZHEIMER'S DISEASE

Dayan B. Goodenowe, PhD (1)*, Vijitha Senanayake, PhD (1), Mitchel A. Kling, MD (2), Jon B. Toledo, MD (3), Tara Smith, PhD (1), Asuka Mochizuki, MS (1), Jessica Tenenbaum, PhD (4), Emily Burke, BS (4), Xianlin Han, PhD (5), Rebecca Baillie, PhD (6), Joseph Lucas, PhD (4), Murali Doraiswamy, MBBS (7), John Q. Trojanowski, MD, PhD (3), Leslie M. Shaw, PhD (3), Sungeun Kim, PhD (8), Andrew J. Saykin, PsyD (8), Rima Kaddurah-Daouk, PhD (7)*, and the Alzheimer Disease Metabolomics Consortium
(1) *Phenomenome Discoveries Inc., Saskatoon, Saskatchewan, Canada;* (2) *Department of Psychiatry and (3) Department of Pathology & Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA;* (4) *Duke University Medical Center, Durham, NC;* (5) *Sanford-Burnham Medical Research Institute, Orlando, FL;* (6) *Rosa & Co. LLC, San Carlos, CA;* (7) *Duke Institute for Brain Sciences, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC;* (8) *Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN*

THEME 11: Clinical Trials and New Therapies

P2-49 PERIPHERAL INFLAMMATORY STATUS IN AMYLOID POSITIVE PATIENTS: EFFECTS OF THE GUT MICROBIOTA

Cattaneo A, PhD (1,2), Cattane N, PhD (1), Altomare D, MS (3), Festari C, MS (3), Pievani M, PhD (3), Pasqualetti P, PhD (4), Muscio C, MS (5), Boccardi M, PhD (3), Prellè A, MD (6), Villani D, MD (7), Gentile S, MD (8), Bellandi D, MD (9), Turla M, MD (10), Dalla Volta G, MD (11), Zanetti O, MD (12), De Fanti Carlo, MD (13), Padovani A, MD (14), Frisoni GB, MD (3), and the INDIA-FBF working group
(1) *IRCCS Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy;* (2) *Stress, Psychiatry and Immunology Laboratory, Department of Psychological Medicine, Institute of Psychiatry, King's College London, London, UK;* (3) *LENITEM-Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy;* (4) *SeSMIT, AFaR, Fatebenefratelli Hospital, Isola Tiberina, Rome; and Unit of Clinical and Molecular Epidemiology;* (5) *Fondazione Europea Ricerca Biomedica (FERB), Centro Eccellenza Alzheimer, Ospedale Briolini, Gazzaniga, Bergamo, Italy;* (6) *A.O. Ospedale Maggiore di Crema, Italy;* (7) *Casa di Cura Figlie di S. Camillo, Crema, Italy;* (8) *Casa di Cura Ancelle della Carità, Crema, Italy;* (9) *Fondazione Istituto Ospedaliero di Sospiro Onlus, Sospiro, Crema, Italy;* (10) *Ospedale di Vallecamonica Esine, Brescia, Italy;* (11) *Istituto Clinico Città di Brescia, Brescia, Italy;* (12) *ATM, IRCCS Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy;* (13) *Centro Alzheimer di Gazzaniga, Bergamo, Italy;* (14) *Department of Medical and Experimental Sciences, Unit of Neurology, Brescia University, Brescia, Italy;* (15) *Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva Geneva, Switzerland*

P2-50 PHARMACOKINETIC PROFILE OF A NOVEL LOW DOSE EXTENDED RELEASE FORMULATION OF AGB101 (LEVETIRACETAM)

Sharon Rosenzweig-Lipson, PhD (1), Steven Mulcahy (1), Ken Payie, PhD (1), Sarah Bullock (2), Elsie Melsopp, PhD (3), Jack James (3), Michela Gallagher, PhD (1)
(1) *AgeneBio, Inc, Baltimore, MD, USA;* (2) *Worldwide Clinical Trials, Early Phase Services, San Antonio, TX, USA;* (3) *AAI Pharma, Wilmington, NC, USA*

P2-51 NEW NEUROPROTECTIVE STRATEGY IN EARLY AD : ARGUMENTS FOR A TRITHERAPY

Jacques Hugon MD PhD, Sarah Gourmaud PhD, Marion Tible PhD, Anne Sophie Carret MD PhD, Francois Mouton-Liger PhD, Pascal Millet MD PhD, Julien Dumurgier MD PhD, Claire Paquet MD PhD
Memory Centre and Inserm UMRS 942 Lariboisière Hospital, APHP and University of Paris Diderot, Paris France

P2-52 REPEATED EMOTIONAL STRESS EXACERBATES AMYLOID -B PEPTIDE INDUCED BRAIN PATHOLOGY IN ALZHEIMER'S DISEASE. POTENTIAL NEUROPROTECTIVE EFFECTS OF NANOWIRED DELIVERY OF CEREBROLYSIN

(1) Hari S SHARMA, (2) José V LAFUENTE, (3) Dafin F MURESANU, (4) Rudy J CASTELLANI, (5) Mark A SMITH, (6) Ranjana PATNAIK, (7) Z Ryan TIAN, (7) Asya OZKIZILCIK, (8) Herbert MÖSSLER, (1) Aruna SHARMA
(1) *Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden;* (2) *Dept of Neurosciences, University of Basque Country, Bilbao, Spain;* (3) *Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania;* (4) *University of Maryland, Dept. of Pathology, Baltimore, MD, USA;* (5) *Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA;* (6) *School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of Technology, Banaras Hindu University, Varanasi, India;* (7) *Dept. Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, USA;* (8) *Ever NeuroPharma, Oberburgau, Austria*

POSTER PRESENTATIONS

POSTER SESSION 2: Friday, November 6th

- P2-53** **TRAUMATIC BRAIN INJURY EXACERBATES AMYLOID B-PEPTIDE INDUCED BRAIN PATHOLOGY IN ALZHEIMER'S DISEASE. SUPERIOR NEUROPROTECTIVE EFFECTS OF TIO₂ NANOWIRED MESENCHYMAL STEM CELLS WITH POLY (D,L-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES LOADED CEREBROLYSIN DELIVERY**
(1) Aruna SHARMA, (2) José V LAFUENTE, (3) Dafin F MURESANU, (4) Lianyuan FENG, (5) Rudy J CASTELLANI, (6) Mark A SMITH, (7) Ranjana PATNAIK, (8) Z Ryan TIAN, (8) Asya OZKIZILCIK, (9) Giovanni TOSI, (9) Barbara RUOZI, (9) Flavio FORNI, (10) Herbert MÖSSLER, (1) Hari Shanker SHARMA
(1) Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden; (2) Dept of Neurosciences, University of Basque Country, Bilbao, Spain; (3) Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania; (4) Dept. Neurology, Bethune Int Peace Hospital Army, Shijiazhuang, Hebei province, China; (5) University of Maryland, Dept. of Pathology, Baltimore, MD, USA; (6) Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA; (7) School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India; (8) Dept. Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, USA; (9) Pharmaceutical Technology and Nanomedicine, TeFarTI research Center, Department of Life Sciences, University of Modena and Reggio Emilia, Italy; (10) Ever NeuroPharma, Oberburgau, Austria
- P2-54** **THE EFFECTS OF MUSIC BASED RELAXATION (MUSIC CARE® APP) ON AUTOBIOGRAPHICAL MEMORY AND ANXIETY IN ALZHEIMER'S DISEASE: RANDOMIZED CONTROLLED TRIAL**
Stéphane Guélin (1,3), Julie Destoutz (3), Bérénice Cagnat (2), Florence Ricciardi (2), Claire Cadilhac (1,2), Jacques Touchon (1)
(1) Service de Neurologie (CMRR), CHRU Montpellier, INSERM U1061, Montpellier, France; (2) Département Universitaire d'Orthophonie, UFR Médecine, Université Montpellier, France; (3) MUSIC CARE, Research & Development, Paris, France
- P2-55** **ABSOLUTE BIOAVAILABILITY AND SAFETY OF A NOVEL RIVASTIGMINE INTRANASAL SPRAY IN HEALTHY ELDERLY INDIVIDUALS**
Timothy Morgan, PhD (1), Bob Soh, MBBS (2)
(1) Lachesis Biosciences Pty Ltd, Warrnambool, VIC, AU (2) Nucleus Network Ltd, Melbourne, VIC, AU
- P2-56** **NEW ANALOGUES OF 7-METHOXYTACRINE AND A POTENTIAL THERAPEUTIC USE IN ALZHEIMER DISEASE**
Jan Ricny (1), Zdena Kristofikova (1), Jana Sirova (1), Jan Korabecny (2), Kamil Kuca (2), Kamil Musilek (3), Daniela Ripova (1)
(1) NUDZ, Topolova 748, 250 67 Klecany, Czech Republic; (2) Faculty of Military Health Science, Hradec Kralove, Czech Republic; (3) Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- P2-57** **APPLICATION OF TAI CHI 6 FORMS IN APPARATUS AND WII FOR BALANCE TRAINING OF ELDERS WITH ALZHEIMER DISEASE**
Alice M.K. Wong, MD (1,2), Yin-Chou Lin, MD, PhD (1), Chia-Wei Wang, MS (1), Albert CK Chen, MD (1), Jean-Lon Chen, MD, PhD (1), Yu-Cheng Pei, MD, PhD (1)
(1) Department of Physical & Rehabilitation medicine, Chang Chung Memorial Hospital, Taiwan, ROC; (2) Institute of Healthy Aging, Chang Gung University, Taiwan, ROC
- P2-58** **AMYPOSOMES®: A NEW NANOMEDICINE FOR THERAPY OF ALZHEIMER DISEASE, WAITING FOR CLINICAL TRIALS**
Massimo Masserini PhD, Simona Mancini, Francesca Re, PhD
School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
- P2-59** **SUVN-502 - SAFETY, TOLERABILITY AND PHARMACOKINETICS OF A POTENT AND SELECTIVE 5-HT₆ RECEPTOR ANTAGONIST IN HEALTHY SUBJECTS**
Ramakrishna Nirogi, PhD, Koteswara Mudigonda, PhD, Kiran Kumar Penta, MS, Gopinadh Bhyrapuneni, PhD, Devender Reddy Ajjala, MS, Nageswararao Muddana, MS, Veera Raghava Chowdary Palacharla, MS, Vinod Kumar Goyal, MS, Santosh Kumar Pandey, MS, Renny Abraham, MS, Pradeep Jayarajan, MS, Rajesh Kumar Badange, MS, and Ramasastry Kambhampati, PhD
Discovery Research, Suven Life Sciences Ltd, Hyderabad, India
- P2-60** **EFFECT OF COMBINATION THERAPY OF CAFFEINATED COFFEE AND SELECTIVE 5-HT₄ AGONIST, PRUCALOPRIDE, IN AN ALZHEIMER'S DISEASE MOUSE MODEL: POSSIBLE IMPLICATIONS ON AMYLOID BETA FORMATION**
M.sc Nouran A.H Al Shehaby (1), Ass. Prof. (3,4), Khaled Abou Aisha, PhD (3), Mona Rady, Prof. (1), Laila Mahran and Ass. Prof. (1,2), Nesrine S. El Sayed
(1) Pharmacology & Toxicology Department, Faculty of Pharmacy & Biotechnology, German University in Cairo, EG; (2) Pharmacology & Toxicology Department, Faculty of Pharmacy, Cairo University, CAI, EG; (3) Pharmaceutical Biology Department, Faculty of Pharmacy & Biotechnology, German University in Cairo, CAI, EG; (4) Pharmaceutical Biology Department, Faculty of Pharmacy, Cairo University, CAU, EG
- P2-61** **IN SILICO EVALUATION AND SYNTHESIS OF NEW MOLECULES AS THERAPEUTIC ALTERNATIVES IN THE ALZHEIMER DISEASE**
García Marín Iohanan Daniel MS- (3), Hernández Rodríguez Maricarmen, Sc.M (2), Rosales-Hernández Martha Cecilia, ScM, ScD (2), Correa-Basurto José, ScM, ScD (1), Manuel Jonathan Fragoso Vázquez, ScM, ScD (3)
(1) Laboratorio de Modelado Molecular y Bioinformática; (2) Laboratorio de Biofísica y Biocatálisis, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, México City, D.F., México; (3) Laboratorio de Investigación Bioquímica. Laboratorio de Investigación Bioquímica, Sección de Estudios de Posgrado e Investigación Plan de San Luis y Díaz Miron s/n, Mexico City, D.F., Mexico